Australia markets closed

Johnson & Johnson (JNJ.DU)

Dusseldorf - Dusseldorf Delayed price. Currency in EUR
Add to watchlist
141.72+0.22 (+0.16%)
At close: 07:31PM CEST
Full screen
Previous close141.50
Open141.84
Bid142.10 x N/A
Ask142.46 x N/A
Day's range141.52 - 142.30
52-week range135.16 - 160.80
Volume30
Avg. volume14
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings date17 July 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Reuters

    J&J-backed startup Rapport files for US IPO

    Rapport, which develops small molecule medicines for patients suffering from central nervous system disorders, is gearing up for a listing as the IPO market recovers from a slump amid increasing hopes of a soft landing for the economy. The company said it will be selling shares in the IPO, but did not disclose how many nor the price range. Rapport's net loss widened to $34.8 million in 2023 from $10.7 million a year earlier.

  • Zacks

    J&J (JNJ) to Boost Dermatology Portfolio With New Acquisition

    Johnson & Johnson (JNJ) inks deal to acquire Proteologix, Inc. for $850 million in cash. The transaction is expected to be closed in mid-2024.

  • Zacks

    Johnson & Johnson (JNJ) Up 5.5% Since Last Earnings Report: Can It Continue?

    Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.